Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, posted on X/Twitter:

“Out in JAMA Oncology a pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC.

pCR was associated with EFS in HER2-E and basal, but not luminal subtypes.

Benefit of dual HER2 blockade (T+L) was restricted to HER2-E tumors.”

View the article attached to the post.
Source: Elisa Agostinetto/X